Literature DB >> 2085704

Activities of endothelin-1 in the vascular network of the rabbit ear: a microangiographic study.

M D Randall1, D H Edwards, T M Griffith.   

Abstract

1. The effects of endothelin-1 on perfusion pressure and on arterial and venous diameters were examined simultaneously in a rabbit isolated ear preparation perfused with physiological buffer. The effects of hypoxia and inhibition of endothelium-derived relaxant factor (EDRF) activity on vascular responses to endothelin-1 were also investigated. 2. Endothelin-1 was potent at increasing perfusion pressure (ED50 = 46.7 +/- 11.0 pmol; Rmax = 85.3 +/- 5.3 mmHg). The potency and maximum reactivity were not significantly affected by hypoxia, inhibition of EDRF activity with 50 microns N-nitro-L-arginine methyl ester (NAME) or a combination of hypoxia and NAME. 3. Endothelin-1 caused equipotent dose-dependent constrictions of the first four generations of arterial branch vessels (G1-G4) but did not influence the diameter of the central ear artery except at high doses of the peptide when paradoxical dilatation' was observed. The peptide was also equipotent at causing constriction of the smaller venous vessels (V1-V4) but did not affect the large veins (V0). 4. Under conditions of hypoxia the potency of endothelin-1 was reduced in G2 and G3, was unaffected in G4 and the peptide did not significantly constrict either G0 or G1. Hypoxia reduced the potency of endothelin-1 in the smaller venous vessels (V1-V4), but conversely unmasked a marked constriction of the large veins (V0), which was not observed under normoxic conditions. 5. NAME 50 micron abolished the vasodilator effects of acetylcholine in this preparation. Inhibition of EDRF activity with NAME under normoxic conditions did not influence the constrictor activity of endothelin-1 on the arterial or venous branch vessels. However, inhibition of EDRF activity under hypoxic conditions prevented the reduction of potency of endothelin-1 as a constrictor of arterial and venous branch vessels which occurred in hypoxia. In the presence of NAME endothelin-1 constricted VO in both normoxia and hypoxia with equipotency but the maximum effect was greatest in hypoxia. 6. In conclusion, endothelin-1 is a powerful vasoconstrictor which acts with greater potency in veins than arteries in the rabbit isolated ear. Although hypoxia does not influence pressor responses it nevertheless alters the spatial pattern of vasoconstriction. In particular hypoxia unmasks constriction of the large veins by endothelin-1. Constriction of these veins was also observed in the absence of EDRF in normoxia, but to a much lesser degree so that the effect of hypoxia may only be partially due to reduced EDRF activity. Hypoxia may therefore directly or indirectly increase the sensitivity of the main veins to endothelin-1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2085704      PMCID: PMC1917830          DOI: 10.1111/j.1476-5381.1990.tb14157.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Production of endothelium derived relaxant factor is dependent on oxidative phosphorylation and extracellular calcium.

Authors:  T M Griffith; D H Edwards; A C Newby; M J Lewis; A H Henderson
Journal:  Cardiovasc Res       Date:  1986-01       Impact factor: 10.787

2.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

3.  Wall stress: a determinant of regional differences in response of frog microvessels to norepinephrine.

Authors:  R W Gore
Journal:  Am J Physiol       Date:  1972-01

4.  The binding of doxepin to histamine H1-receptors in guinea-pig and rat brain.

Authors:  J Aceves; S Mariscal; K E Morrison; J M Young
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

5.  Anoxia and endothelium-dependent reactivity of the canine femoral artery.

Authors:  J G De Mey; P M Vanhoutte
Journal:  J Physiol       Date:  1983-02       Impact factor: 5.182

6.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.

Authors:  R F Furchgott; J V Zawadzki
Journal:  Nature       Date:  1980-11-27       Impact factor: 49.962

7.  Hypoxia releases a vasoconstrictor substance from the canine vascular endothelium.

Authors:  G M Rubanyi; P M Vanhoutte
Journal:  J Physiol       Date:  1985-07       Impact factor: 5.182

8.  EDRF coordinates the behaviour of vascular resistance vessels.

Authors:  T M Griffith; D H Edwards; R L Davies; T J Harrison; K T Evans
Journal:  Nature       Date:  1987 Oct 1-7       Impact factor: 49.962

9.  Effects of basal and acetylcholine-induced release of endothelium-derived relaxing factor on contraction to alpha-adrenoceptor agonists in a rabbit artery and corresponding veins.

Authors:  J C McGrath; S Monaghan; A G Templeton; V G Wilson
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

10.  Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium.

Authors:  J G De Mey; P M Vanhoutte
Journal:  Circ Res       Date:  1982-10       Impact factor: 17.367

View more
  3 in total

1.  Differential effects of L-arginine on the inhibition by NG-nitro-L-arginine methyl ester of basal and agonist-stimulated EDRF activity.

Authors:  M D Randall; T M Griffith
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

2.  Modulation of vasodilatation to levcromakalim by hypoxia and EDRF in the rabbit isolated ear: a comparison with pinacidil, sodium nitroprusside and verapamil.

Authors:  M D Randall; T M Griffith
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

3.  Effects of BRL 38227, sodium nitroprusside and verapamil on collateral perfusion following acute arterial occlusion in the rabbit isolated ear.

Authors:  M D Randall; T M Griffith
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.